Clinical Trial Detail

NCT ID NCT03696212
Title Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements yes
Sponsors Arrys Therapeutics
Indications

lung adenocarcinoma

Therapies

Grapiprant + Pembrolizumab

Age Groups: senior adult

Additional content available in CKB BOOST